Last reviewed · How we verify
Aptosyn (EXISULIND)
Aptosyn works by binding to the endothelin-1 receptor, which is involved in cell growth and proliferation.
Aptosyn (Exisulind) is a small molecule modality targeting the endothelin-1 receptor. It is currently owned by a pharmaceutical company, but its original developer is not specified. Aptosyn's commercial status and approved indications are unknown. The drug's half-life, bioavailability, and generic manufacturers are also not publicly available. As a result, its off-patent status cannot be confirmed.
At a glance
| Generic name | EXISULIND |
|---|---|
| Target | Mitogen-activated protein kinase 1, Endothelin-1 receptor, Aldose reductase |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
Think of Aptosyn like a key that fits into a lock on the surface of cells. When it binds to the endothelin-1 receptor, it can help slow down or stop the growth of certain cells that might be contributing to a disease. This can be helpful in treating conditions where cell growth is out of control.
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer (PHASE2)
- Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer (PHASE2)
- Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer (PHASE2)
- Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy (PHASE2)
- Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer (PHASE2)
- Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis (PHASE2,PHASE3)
- Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer (PHASE2)
- Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aptosyn CI brief — competitive landscape report
- Aptosyn updates RSS · CI watch RSS